FTY720 has been proposed as an anti-cancer agent [18, 40], however its efficacy may be limited with clinical toxicities including transient bradycardia, macular oedema, and brain inflammation, thought to be due to the effects of FTY720-P on sphingosine-1-phosphate receptors [41, 42]. This evidence concerns the gene S1PR1 and brain inflammatory disease.